Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.

Autor: Gómez-Labrador C; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain., Ricart E; Gastroenterology Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBEREHD, 08036 Barcelona, Spain., Iborra M; Gastroenterology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain., Iglesias E; Gastroenterology Unit, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14004 Córdoba, Spain., Martín-Arranz MD; Gastroenterology Unit, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Hospital La Paz Institute for Health Research, 28046 Madrid, Spain., de Castro L; Gastroenterology Unit, Hospital Álvaro Cunqueiro, Grupo de Investigación en Patología Digestiva, Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur) SERGAS, UVIGO, 36312 Vigo, Spain., De Francisco R; Gastroenterology Unit, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain., García-Alonso FJ; Gastroenterology Unit, Hospital Universitario Río Hortega, 47012 Valladolid, Spain., Sanahuja A; Gastroenterology Unit, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain., Gargallo-Puyuelo CJ; Gastroenterology Unit, Hospital Clínico Universitario Lozano Blesa, IIS Aragón, 50009 Zaragoza, Spain., Mesonero F; Gastroenterology Unit, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain., Casanova MJ; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain., Mañosa M; Gastroenterology Unit, Hospital Universitari Germans Trias i Pujol, and CIBEREHD, 08916 Badalona, Spain., Rivero M; Gastroenterology Unit, Hospital Universitario de Valdecilla and Instituto de Investigación Sanitaria Valdecilla (IDIVAL), 39008 Santander, Spain., Calvo M; Gastroenterology Unit, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Madrid, Spain., Sierra-Ausin M; Gastroenterology Unit, Complejo Asistencial Universitario de León, 24008 León, Spain., González-Muñoza C; Gastroenterology Unit, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain., Calvet X; Gastroenterology Unit, Parc Taulí, Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí, Departament de Medicina, Universitat Autònoma de Barcelona and CIBEREHD, 08208 Sabadell, Spain., García-López S; Gastroenterology Unit, Hospital Universitario Miguel Servet, e Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain., Guardiola J; Gastroenterology Unit, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Universitat de Barcelona, 08907 Barcelona, Spain., Arias García L; Gastroenterology Unit, Hospital Universitario de Burgos, 09006 Burgos, Spain., Márquez-Mosquera L; Gastroenterology Unit, Hospital del Mar, Barcelona and IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain., Gutiérrez A; Gastroenterology Unit, Hospital General Universitario de Alicante, CIBEREHD, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), 03010 Alicante, Spain., Zabana Y; Gastroenterology Unit, Hospital Universitario Mútua Terrassa, and CIBEREHD, 08221 Terrassa, Spain., Navarro-Llavat M; Gastroenterology Unit, Complex Hospitalari Universitari Moisès Broggi, 08970 Barcelona, Spain., Lorente Poyatos R; Gastroenterology Unit, Hospital General Universitario de Ciudad Real, 13005 Ciudad Real, Spain., Piqueras M; Gastroenterology Unit, Consorci Sanitari Terrassa, 08227 Terrassa, Spain., Torrealba L; Gastroenterology Unit, Hospital Universitario Dr. Josep Trueta, 17007 Girona, Spain., Bermejo F; Gastroenterology Unit, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain., Ponferrada-Díaz Á; Gastroenterology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain., Pérez-Calle JL; Gastroenterology Unit, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain., Barreiro-de Acosta M; Gastroenterology Unit, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain., Tejido C; Gastroenterology Unit, Complexo Hospitalario Universitario de Ourense, 32005 Ourense, Spain., Cabriada JL; Gastroenterology Unit, Hospital de Galdakao-Usansolo, 48960 Galdakao, Spain., Marín-Jiménez I; Gastroenterology Unit, Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense de Madrid, 28007 Madrid, Spain., Roncero Ó; Gastroenterology Unit, Complejo Hospitalario la Mancha Centro, 13600 Alcázar de San Juan, Spain., Ber Y; Gastroenterology Unit, Hospital Universitario San Jorge, 22004 Huesca, Spain., Fernández-Salazar L; Gastroenterology Unit, Hospital Clínico Universitario de Valladolid (SACYL), Universidad de Valladolid, 47003 Valladolid, Spain., Camps Aler B; Gastroenterology Unit, Hospital General de Granollers, 08402 Granollers, Spain., Lucendo AJ; Gastroenterology Unit, Hospital General de Tomelloso, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), and CIBEREHD, 13700 Tomelloso, Spain., Llaó J; Gastroenterology Unit, Althaia Xarxa Assistencial Universitaria de Manresa, 08243 Barcelona, Spain., Bujanda L; Gastroenterology Unit, Hospital Universitario Donostia, Instituto Biodonostia, CIBEREHD and Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain., Muñoz Villafranca C; Gastroenterology Unit, Hospital de Basurto, 48013 Bilbao, Spain., Domènech E; Gastroenterology Unit, Hospital Universitari Germans Trias i Pujol, and CIBEREHD, 08916 Badalona, Spain.; Universitat Autònoma de Barcelona, 08193 Barcelona, Spain., Chaparro M; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain., Gisbert JP; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28006 Madrid, Spain.
Jazyk: angličtina
Zdroj: Pharmaceutics [Pharmaceutics] 2024 May 08; Vol. 16 (5). Date of Electronic Publication: 2024 May 08.
DOI: 10.3390/pharmaceutics16050629
Abstrakt: Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje